Stroke vs Heart Failure — Clinical Trial Comparison
Stroke
Brain injury from blocked or bleeding blood vessels
VS
Heart Failure
Heart cannot pump blood effectively
Stroke and heart failure are both major cardiovascular diseases with significant UK research investment. Stroke trials span acute interventions (thrombolysis, thrombectomy) through rehabilitation and prevention, while heart failure trials focus on improving cardiac function, reducing hospitalisations, and extending survival. Both conditions share risk factors, making cardiovascular prevention trials relevant to both patient groups.
Key Differences at a Glance
| Feature | Stroke | Heart Failure |
|---|---|---|
| Primary symptoms | Sudden face/arm weakness, speech difficulty, vision loss | Breathlessness, fluid retention, fatigue, exercise intolerance |
| Common subtypes | Ischaemic (85%), haemorrhagic (15%), TIA, recovery phase | HFrEF, HFpEF, HFmrEF, acute decompensated, chronic |
| Severity scoring | NIHSS (acute), mRS (outcome), Barthel Index (function) | NYHA Class I-IV, LVEF %, NT-proBNP, KCCQ |
| Urgency | Hyperacute — time-critical treatment window (4.5 hours) | Chronic management — acute exacerbations need urgent care |
| NICE first-line | Thrombolysis, thrombectomy, antiplatelet, statin, rehab | ACEi/ARB + beta blocker + SGLT2i + MRA |
| Prevalence in UK | ~100,000 strokes/year; 1.3 million survivors | ~1 million diagnosed; 200,000 new cases/year |
Clinical Trial Availability
| Trial Aspect | Stroke | Heart Failure |
|---|---|---|
| UK trials actively recruiting | 50–80 studies | 60–100 studies |
| Most common trial phase | Phase 2–4 | Phase 2–3 |
| Top interventions tested | Thrombolysis agents, neuroprotectives, rehabilitation tech, stem cells, secondary prevention | SGLT2 inhibitors, ARNI, gene therapy, stem cells, cardiac devices, remote monitoring |
| Acute treatment trials | Major focus (time-critical interventions) | Limited (acute decompensation management) |
| Rehabilitation trials | Major focus (VR, robotics, brain stimulation) | Exercise-based rehabilitation |
| Prevention trials | Antiplatelet, anticoagulant, blood pressure management | Comorbidity management (AF, hypertension, diabetes) |
Exciting Emerging Treatments
Stroke Trials
- Extended thrombolysis windows — pushing beyond 4.5 hours with advanced imaging
- Neuroprotective agents — protecting brain cells during acute stroke
- VR-based rehabilitation — immersive environments for motor recovery
- Brain stimulation (TMS/tDCS) — enhancing neuroplasticity
- Stem cell therapy — regenerating damaged brain tissue
- Digital therapeutics — app-based cognitive and motor rehabilitation
Heart Failure Trials
- SGLT2 inhibitors — heart failure benefit independent of diabetes status
- Gene therapy — delivering cardiac genes (SERCA2a, adenylate cyclase)
- Cardiac stem cell therapy — regenerating damaged myocardium
- Implantable sensors — continuous haemodynamic monitoring
- Cardiac myosin activators — directly improving contractility
- Remote monitoring platforms — AI-driven early deterioration detection
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
Stroke Trial Criteria
- Confirmed stroke diagnosis with neuroimaging (CT/MRI)
- Time from symptom onset critical for acute trials (typically within 4.5–24 hours)
- Rehabilitation trials: stable post-stroke with specific deficit (motor, speech, cognitive)
- NIHSS score range specified for acute trials (defining stroke severity)
- Prevention trials: prior stroke/TIA or high-risk vascular profile
Heart Failure Trial Criteria
- LVEF measurement classifies HF type (≤40% HFrEF, ≥50% HFpEF)
- NT-proBNP level commonly required for enrolment threshold
- Recent HF hospitalisation may be required (within 6–12 months)
- Stable on optimal medical therapy for minimum period before randomisation
- Device trials may require specific NYHA class and no existing device
Heart Failure Trials
Find actively recruiting heart failure clinical trials across the UK
Heart Failure TrialsFrequently Asked Questions
Can I join a clinical trial if I have both Stroke and Heart Failure?
It depends on the specific trial. Many trials allow comorbid conditions as long as the primary condition being studied is clearly dominant. Some trials explicitly exclude patients with significant overlapping conditions. Always check the eligibility criteria carefully and discuss with both the trial team and your specialist.
Which condition has more clinical trials available in the UK?
Stroke typically has more actively recruiting trials in the UK. However, Heart Failure trials are often more novel in approach, particularly in emerging areas like gene therapy and precision medicine.
What should I consider when choosing between trials for these conditions?
Consider which condition impacts your quality of life most, what treatments you've already tried, the trial phase (earlier phases are more experimental), the time commitment involved, and whether the trial offers access to treatments not otherwise available. Your specialist can help you prioritise.